Clinical trial NCT02211859: Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit
Official title: An Open Phase I Repeated Dose Escalation Study of BI 2536 BS Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Neoplasms
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2014-08-08
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Primary: Maximum tolerated dose (MTD) Secondary: Determination of the pharmacokinetic profile of BI 2536. Assessment of safety and efficacy.


Eligibility criteria: Inclusion criteria:

* Patients with confirmed diagnosis of advanced, non resectable and/or metastatic solid tumours, who have failed conventional treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment
* Evaluable tumour deposits
* Age 18 years or older
* Life expectancy of at least six months
* Written informed consent consistent with international conference of harmonization (ICH) - good clinical practice (GCP) and local legislation
* Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2
* Full recovery from all therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapies

Exclusion Criteria:

* Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol
* Pregnancy or breastfeeding
* Active infectious disease
* Known brain metastases
* Second malignancy requiring therapy
* Absolute neutrophil count less than 1500/mm3
* Platelet count less than 100 000/mm3
* Bilirubin greater than 1.5 mg/dl (\> 26 μmol/L)
* Aspartate amino transferase (AST) and/or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal)
* Serum creatinine greater than 1.5 mg/dl (\> 132 μmol/L)
* Women and men who are sexually active and unwilling to use a medically acceptable method of contraception
* Treatment with other investigational drugs or participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial (except for present trial drug)

Primary outcomes:
measure: Determination of the maximum tolerated dose (MTD) by occurrence of dose limiting toxicities (DLT)
timeFrame: up to 3 weeks
Secondary outcomes:
measure: Number of patients with drug-related adverse events
timeFrame: up to 24 days after last drug administration
measure: Number of patients with abnormal laboratory findings
timeFrame: up to 24 days after last drug administration
measure: Change in Eastern Cooperative Oncology Group (ECOG) performance score
timeFrame: baseline, up to 24 days after last drug administration
measure: Number of patients with clinically significant changes in vital signs
timeFrame: up to 24 days after last drug administration
measure: Number of patients with objective tumor response
timeFrame: up to 24 days after last drug administration
measure: Cmax (maximum concentration of the analyte in plasma)
timeFrame: up to 264 hours after drug administration
measure: tmax (time from dosing to maximum concentration)
timeFrame: up to 264 hours after drug administration
measure: AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
timeFrame: up to 264 hours after drug administration
measure: %AUC0-tz (the percentage of the AUC0-∞ that is obtained by extrapolation)
timeFrame: up to 264 hours after drug administration
measure: λz (terminal rate constant in plasma)
timeFrame: up to 264 hours after drug administration
measure: t1/2 (terminal half-life of the analyte in plasma)
timeFrame: up to 264 hours after drug administration
measure: MRT (mean residence time of the analyte in the body after intravenous administration)
timeFrame: up to 264 hours after drug administration
measure: CL (total clearance of the analyte in the plasma after intravascular administration)
timeFrame: up to 264 hours after drug administration
measure: Vz (apparent volume of distribution during the terminal phase λz following an intravascular dose)
timeFrame: up to 264 hours after drug administration
measure: Vss (apparent volume of distribution at steady state following intravascular administration)
timeFrame: up to 264 hours after drug administration
Other outcomes:
Locations:
Study officials:
References: